Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target

Benzinga Newsdesk www.benzinga.com Negative 49.1%

Neg 49.1% Neu 0% Pos 0%

Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $31 price target.

Comments

No comments yet. Be the first!